ahlam1399
05-26-2015, 01:08 PM
AstraZeneca hit after psoriasis drug linked to suicide fears
LONDON (Reuters) - AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46a4c724/sc/21/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=bRJvqtZZLgY:5VxNhBEN8Ec:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=bRJvqtZZLgY:5VxNhBEN8Ec:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=bRJvqtZZLgY:5VxNhBEN8Ec:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=bRJvqtZZLgY:5VxNhBEN8Ec:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=bRJvqtZZLgY:5VxNhBEN8Ec:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/bRJvqtZZLgY
LONDON (Reuters) - AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46a4c724/sc/21/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=bRJvqtZZLgY:5VxNhBEN8Ec:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=bRJvqtZZLgY:5VxNhBEN8Ec:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=bRJvqtZZLgY:5VxNhBEN8Ec:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=bRJvqtZZLgY:5VxNhBEN8Ec:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=bRJvqtZZLgY:5VxNhBEN8Ec:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/bRJvqtZZLgY